Corporate R&D leaders face a fundamental strategic question: should we build internal capabilities, acquire companies with the technology we need, or partner with external research organizations? Melan helps corporations answer this question through portfolio intelligence and partnership strategy.
The build vs. buy vs. partner framework is well-established in corporate strategy, but its application to R&D requires understanding the specific dynamics of research capability development. Each option carries distinct cost structures, timelines, risk profiles, and strategic implications.
The Build Option: Internal R&D
Building internal R&D capabilities offers maximum control and long-term strategic advantage. However, it requires significant capital investment, long time horizons, and the ability to attract and retain specialized research talent.
Best when:
- The technology is core to competitive advantage and needs ongoing development
- The organization has the patience and resources for 5-10 year investment horizons
- Internal talent can be recruited and retained in the specific domain
- Speed to market is less critical than depth of capability
Risks:
- High fixed costs regardless of research output
- Difficulty recruiting specialized researchers in competitive fields
- Risk of internal groupthink and stale research directions
- Long time to capability maturity
The Buy Option: M&A and Licensing
Acquiring companies or licensing existing technology provides immediate capability but at a premium cost. M&A in deep tech carries particularly high execution risk given the difficulty of valuing early-stage technology and integrating research teams.
Best when:
- Technology is mature enough for due diligence
- Speed to market is the primary strategic driver
- The target company’s team and culture can be integrated
- Market position justifies acquisition premium
Risks:
- High upfront cost and integration complexity
- Valuation uncertainty in early-stage technology
- Key talent departure post-acquisition
- Limited ability to shape research direction post-acquisition
The Partner Option: Research Partnerships
Research partnerships offer access to external capabilities without the fixed costs of building or the premium of buying. They provide flexibility, access to multiple research groups simultaneously, and the ability to shape emerging research directions.
Best when:
- The capability gap is scientific, not operational
- Multiple research groups could address the need
- The technology is too early for M&A due diligence
- The organization needs to test a domain before committing to build or buy
Risks:
- Less control than internal R&D
- IP negotiation complexity
- Partnership governance overhead
- Cultural mismatches between corporate and academic partners
The Decision Framework
The right choice depends on three factors: strategic criticality, technology maturity, and internal capability. Technology that is both strategically critical and mature enough for due diligence may justify acquisition. Technology that is strategically critical but early-stage may warrant a build approach. Technology that is important but not core is often best accessed through partnerships.
Research partnerships also serve as a lower-risk entry point. A two-year partnership can validate a technology domain at a fraction of the cost of an acquisition or internal build, providing the data needed for larger investment decisions.
The Melan Approach
Melan helps corporations evaluate build vs. buy vs. partner decisions through portfolio intelligence and technology scouting. By mapping the external research landscape against internal capabilities, organizations can make informed decisions about where to invest in each approach.
Melan’s partnership strategy services help organizations that choose the partner option design structures that maximize the probability of successful outcomes.
Ready to evaluate your R&D strategy? Melan offers a free consultation to assess your build vs. buy vs. partner options.
